Skip to main content
S&P 5007,675.36+0.68%DOW52,297.03+0.16%NASDAQ26,188.61+0.90%BTC$80,162.00-0.69%ETH$2,322.26-1.46%GOLD$4,037.80+0.75%OIL$102.07-1.16%
Smart Investors Daily
SID Premium
SI

NASDAQ · SIBN

SI-BONE, Inc.

Healthcare · Medical - Devices

$21.48

Down-$0.33 (-1.51%)

Updated Oct 26, 2026, 5:14 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
816.58M
P/E ratio
-33.89
Dividend yield
0.00%
52-week range
$11.48 – $21.89
Volume
469.09K
Avg. volume
529.81K

Price performance · SIBN

SIBN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 23, 2026

SIBN closed at $21.48 after 20 trading sessions, up 14.50% for the selected period.

Last close
$21.48
Period change
+14.50%
Period low
$18.08
Period high
$21.56
Daily close
View OHLC price history
SIBN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 23, 2026$21.21$21.63$20.665$21.48469.09K
Oct 22, 2026$20.93$21.73$20.93$21.56527.76K
Oct 21, 2026$20.35$21.22$20.275$20.82812.81K
Oct 20, 2026$19.90$20.59$19.85$20.54640.8K
Oct 19, 2026$19.38$19.92$19.38$19.66338.15K
Oct 16, 2026$19.91$20.02$19.19$19.681.17M
Oct 15, 2026$19.51$20.0525$19.51$19.91467.24K
Oct 14, 2026$19.62$19.865$19.415$19.47407.81K
Oct 13, 2026$20.19$20.26$19.66$19.68442.59K
Oct 12, 2026$19.40$20.11$19.36$20.10553.69K
Oct 9, 2026$18.90$19.44$18.90$19.37555.92K
Oct 8, 2026$18.98$19.12$18.42$18.86762.77K
Oct 7, 2026$19.27$19.69$18.98$19.10547.63K
Oct 6, 2026$19.92$20.00$19.21$19.55538.73K
Oct 5, 2026$18.26$19.84$18.26$19.81632.02K
Oct 2, 2026$18.60$18.80$17.95$18.08547.32K
Oct 1, 2026$18.87$19.04$18.27$18.41652.99K
Sep 30, 2026$19.15$19.27$18.80$18.80640.21K
Sep 29, 2026$18.92$19.60$18.61$19.15624.17K
Sep 28, 2026$18.59$18.815$18.40$18.76461.56K

Latest SIBN news

The latest Smart Investors Daily articles mentioning SIBN.

Stock researchCompany · Overview

SIBN research

Overview

Company profile and research snapshot.

Company profile

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.67
Implied upside
—
Analysts
—
SIBN recent ratings
DateFirmRatingTarget
Oct 14, 2026Truist SecuritiesBuy—
Aug 4, 2026TD CowenBuy—
Aug 4, 2026UBSBuy—
Aug 4, 2026Truist SecuritiesBuy—
Jul 28, 2026UBSBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 19, 2026

SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026

SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the third quarter of 2026 after market close on Monday, November 2, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by regi

Yahoo · Sep 28, 2026

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis

FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density boneSANTA CLARA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the iFuse Granite Onyx System (Onyx). This is SI-BONE’s first product addressing the problem of compromised bone which

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By